- About Us
- Nano-Social Network
- Nano Consulting
- My Account
June 17th, 2007
Tempo Hurries To Target Nanoparticle Combo Drugs
Tempo Pharmaceuticals Inc. isn't wasting any time. Since its founding in late 2006, the Cambridge, Mass.-based company has raised Seed and Series A financings, licensed core technology, hired 15 employees, started partnership discussions and begun the process of translating its platform into a product fit for clinical trials.
Yet founder and CEO Alan Crane said the name Tempo refers not to the company's frenetic pace, but to the "temporal release" of multiple drugs from its Nanocell platform technology.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Explaining how 2-D materials break at the atomic level January 20th, 2017